



Attorney Docket No. 701826-050990

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: LAZARUS, Alan H., et al.
Filed: 10 November 2000
Serial No.: 09/709,249
Title: A METHOD FOR PREVENTING AND
INHIBITING HUMAN HLA ALLOIMMUNE
RESPONSE TO PLATELET TRANSFUSION
Examiner: EWOLDT, Gerald R.
Group Art Unit: 1644

#15/B
JUL 02 2003
RECEIVED
TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

6/27/2003
Date

Nicole M. Gignac
(type or print name of person mailing paper)

Nicole M. Gignac
Signature of person mailing paper

Mail Stop Non-Fee Amendment

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

AMENDMENT

Sir:

In response to the Office Action dated April 3, 2003 please amend the above-identified patent application as follows:

A listing of the disclosure amendments appears on page 2 of this paper.

A listing of the claims appears on page 3 of this paper.

Remarks/Arguments appear on page 4 of this paper.

In re Application of: LAZARUS, Alan H., et al.

Filed: 10 November 2000

Serial No.: 09/709,249

LISTING OF DISCLOSURE AMENDMENTS

On page 4, please amend the first paragraph (paragraph 12) of the specification as follows:

B¹ The monoclonal antibody can be for example W6/32, L368, and MA2.1 ATCC accession numbers HB-95, HB-149, and HB-54, respectively wherein such antibodies are readily available without restrictions from the American Type Culture Collection (ATCC).